Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.…
Azenta (AZTA) Stock Looks Reasonable With Sales Support In Place
Azenta (NASDAQ: AZTA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector.
The shares were at 44.80 USD on 20 November 2026, up 52.5% over 52 weeks. Its 52-week range is 15.93 USD to 50.05 USD: the price is 10.5% below the high and 181.2% above the low.
Its market capitalisation is 1.87B USD.
Azenta reports return on equity of -3.2%, an operating margin of -3.3% and revenue up 5.1% year over year.
It holds more cash than debt, a net cash position of 280.81M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 52.60 USD is 17.4% above the current price. The next earnings report is expected on 3 February 2027.